---
layout: minimal-medicine
title: Gadoversetamide
---

# Gadoversetamide
### Generic Name
Gadoversetamide

### Usage
Gadoversetamide is a gadolinium-based contrast agent used in conjunction with magnetic resonance imaging (MRI) scans.  Its primary use is to enhance the visualization of lesions and abnormalities in the central nervous system (CNS) – the brain and spinal cord –  in patients with suspected blood-brain barrier disruption or abnormal vascularity.  It's also indicated for improving the visualization of lesions in the liver of patients strongly suspected of having liver structural abnormalities based on prior computed tomography (CT) scans.  This enhancement allows for clearer imaging and more accurate diagnosis of various conditions.

### Dosage
**Adult Dosage:** For both CNS and liver imaging, the recommended intravenous (IV) dose is 0.1 mmol/kg (or 0.2 mL/kg) administered as a rapid bolus injection over 1-2 mL per second, followed by a 5 mL saline flush.  Imaging should ideally be completed within 60 minutes of injection.

**Pediatric Dosage:**  The safety and efficacy of gadoversetamide in pediatric patients have not been established.

**Dosage Adjustments:**

* **Hepatic Impairment:**  No specific dosage adjustments are recommended by the manufacturer for patients with hepatic impairment.
* **Renal Impairment:**  For patients with a glomerular filtration rate (GFR) of ≥30 mL/minute/1.73 m², while no dosage adjustment is explicitly stated, caution is advised. The risk of nephrogenic systemic fibrosis (NSF) increases with decreasing renal function.  Gadoversetamide is contraindicated in patients with a GFR <30 mL/minute/1.73 m².  If administered to patients already undergoing hemodialysis, prompt hemodialysis post-administration (within 3 hours) should be considered. Peritoneal dialysis is likely less effective at clearing gadolinium.


### Side Effects
**Common Side Effects (≥1%):**

* Injection site discomfort
* Headache
* Dizziness
* Paresthesia (numbness or tingling)
* Pain
* Vasodilation
* Dysgeusia (altered taste)
* Nausea
* Abdominal pain
* Diarrhea
* Dyspepsia (indigestion)
* Asthenia (weakness)
* Back pain
* Rhinitis (inflammation of the nasal mucous membranes)

**Less Common, but Serious Side Effects (<1%):**  A wide range of less frequent but potentially serious side effects have been reported, including anaphylaxis, nephrogenic systemic fibrosis (NSF), and various other allergic or hypersensitivity reactions.  See the detailed list in the provided text.  Any concerning side effects should be reported immediately to a healthcare provider.

### How it Works
Gadoversetamide is a paramagnetic contrast agent.  It contains gadolinium, a rare earth metal, chelated to versetamide.  When exposed to a strong magnetic field during an MRI scan, the gadolinium alters the magnetic properties of surrounding water molecules. This alteration enhances the signal detected by the MRI machine, leading to improved contrast and visualization of tissues with abnormal vascularity or blood-brain barrier permeability.

### Precautions
**Contraindications:** Gadoversetamide is contraindicated in patients with:

* Hypersensitivity to gadolinium, versetamide, or any formulation component.
* Chronic, severe kidney disease (GFR <30 mL/minute/1.73 m²)
* Acute kidney injury


**Warnings:**

* **Nephrogenic Systemic Fibrosis (NSF):** This is a serious, potentially fatal condition characterized by fibrosis of the skin, muscles, and internal organs. The risk of NSF is significantly increased in patients with impaired kidney function.  Gadoversetamide should be used with extreme caution, or avoided entirely, in patients with renal impairment.  Careful assessment of renal function is crucial before administration.

* **Hypersensitivity Reactions:**  Gadoversetamide can cause allergic reactions, ranging from mild to severe (anaphylaxis). Patients should be monitored closely for any signs of hypersensitivity during and after administration.

* **Pregnancy and Lactation:** Gadoversetamide is categorized as pregnancy category C. While the amount of gadolinium crossing the placenta is unknown, pregnant patients may be at increased risk of gadolinium retention.  Use during pregnancy should only be considered if the benefits outweigh the risks and essential information cannot be obtained by other means. The excretion of gadoversetamide into breast milk is unknown; however, due to low expected excretion and low infant absorption, breastfeeding may generally continue.

* **Renal Function Monitoring:** Renal function (GFR) should be assessed before administration, particularly in older adults or those with risk factors for renal impairment (hypertension, diabetes).

### FAQs

* **Q: How long does it take for gadoversetamide to be eliminated from the body?** A:  The exact elimination time varies depending on individual renal function.  Patients with normal renal function generally clear it more quickly than those with impaired function.

* **Q: What should I do if I experience side effects?** A: Report any side effects, especially serious ones, to your healthcare provider immediately.

* **Q: How is gadoversetamide stored?** A:  Follow the specific storage instructions provided by your healthcare professional or on the product packaging.

* **Q: Can gadoversetamide be used in all patients undergoing MRI?** A: No, its use is contraindicated in patients with severe kidney disease and acute kidney injury and should be used cautiously in those with reduced renal function. It's crucial to assess the patient's renal function before administering the contrast agent.

* **Q: Are there alternative contrast agents for MRI?** A: Yes, several other contrast agents are available.  Your doctor will determine the most appropriate option based on your individual needs and medical history.

**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.
